|
|
Blood, 15 December 2005, Vol. 106, No. 13, pp. 4152-4158.
Prepublished online as a Blood First Edition Paper on September 6, 2005; DOI 10.1182/blood-2005-05-2048.
 Previous Article | Table of Contents | Next Article 
HEMOSTASIS, THROMBOSIS, AND VASCULAR BIOLOGY
Predictive value of persistent versus transient antiphospholipid antibody subtypes for the risk of thrombotic events in pediatric patients with systemic lupus erythematosus
Christoph Male,
Denise Foulon,
Hugh Hoogendoorn,
Patricia Vegh,
Earl Silverman,
Michèle David, and
Lesley Mitchell
From the Children's Hospital, Medical University of Vienna, Austria; Henderson Research Centre, McMaster University, Hamilton, ON; Hospital for Sick Children, Toronto, ON; Hôpital Ste Justine, Montreal, QC; and Stollery Children's Hospital, Edmonton, AB, Canada.
Study objectives were to determine, in children with systemic lupus erythematosus (SLE), (1) the association of antiphosholipid antibody (APLA) subtypes with thrombotic events (TEs) and (2) the predictive value of persistent versus transient antibodies for TEs. This is a cohort study of 58 SLE children in whom lupus anticoagulants (LAs), anticardiolipin antibodies (ACLAs), anti– 2-glycoprotein-I (anti–2-GPI), and antiprothrombin (anti-PT) were assessed on at least 2 occasions (more than 3 months apart). Antibodies were classified as persistent (positive on at least 2 occasions) or transient (positive once). Outcomes were symptomatic TEs confirmed by objective radiographic tests identified retrospectively and prospectively. Seven of the 58 patients (12%) had 10 TEs; 5 patients had TEs during prospective follow-up. Persistent LAs showed the strongest association with TEs (P < .001). Persistent ACLAs (P = .003) and anti–2-GPI (P = .002) were significantly associated with TEs; anti-PT (P = .063) showed a trend. Persistent or transient LAs and anti–2-GPI showed similar strength of association, while ACLAs and anti-PT were no longer associated with TEs. Positivity for multiple APLA subtypes showed stronger associations with TEs than for individual APLA subtypes because of improved specificity. Lupus anticoagulant is the strongest predictor of the risk of TEs; other APLA subtypes provide no additional diagnostic value. Anticardiolipin antibodies and anti-PT require serial testing because only persistent antibodies are associated with TEs.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
G. W. Moore, S. Rangarajan, and G. F. Savidge
The Activated Seven Lupus Anticoagulant Assay Detects Clinically Significant Antibodies
Clinical and Applied Thrombosis/Hemostasis,
July 1, 2008;
14(3):
332 - 337.
[Abstract]
[PDF]
|
|
|
|
|
|
|
P. Monagle, E. Chalmers, A. Chan, G. deVeber, F. Kirkham, P. Massicotte, and A. D. Michelson
Antithrombotic Therapy in Neonates and Children: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)
Chest,
June 1, 2008;
133(6_suppl):
887S - 968S.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. Descloux, I. Durieu, P. Cochat, D. Vital Durand, J. Ninet, N. Fabien, and R. Cimaz
Paediatric systemic lupus erythematosus: prognostic impact of antiphospholipid antibodies
Rheumatology,
February 1, 2008;
47(2):
183 - 187.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Martinez-Berriotxoa, G. Ruiz-Irastorza, M.-V. Egurbide, M. Garmendia, J. Gabriel Erdozain, I. Villar, and C. Aguirre
Transiently positive anticardiolipin antibodies and risk of thrombosis in patients with systemic lupus erythematosus
Lupus,
October 1, 2007;
16(10):
810 - 816.
[Abstract]
[PDF]
|
|
|
|
|
|
|
T. Avcin and E. Silverman
Review: Antiphospholipid antibodies in pediatric systemic lupus erythematosus and the antiphospholipid syndrome
Lupus,
August 1, 2007;
16(8):
627 - 633.
[Abstract]
[PDF]
|
|
|
|
|
|
|
S. M. Abo and V. A. DeBari
Laboratory Evaluation of the Antiphospholipid Syndrome
Ann. Clin. Lab. Sci.,
January 1, 2007;
37(1):
3 - 14.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
